Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis

被引:0
|
作者
te Kampe, Ritch [1 ,2 ,3 ]
Nielsen, Sabrina Mai [4 ,5 ]
Hotea, Ioana [6 ]
van Durme, Caroline [1 ,7 ]
Christensen, Robin [4 ,5 ]
Boonen, Annelies [1 ,2 ]
机构
[1] Maastricht Univ Med Ctr, Div Rheumatol, Dept Internal Med, POB 5800, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
[3] VieCuri Med Ctr, Dept Rheumatol, Venlo, Netherlands
[4] Bispebjerg & Frederiksberg Hosp, Sect Biostat & Evidence Based Res, Copenhagen, Denmark
[5] Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, Res Unit Rheumatol, Odense, Denmark
[6] Univ Med & Pharm, Dept Rheumatol, Cluj Napoca, Romania
[7] Ctr Hosp Chretien, Liege, Belgium
关键词
Gout; Urate-lowering therapy; Contextual factors; Renal function; Effect modification; DOUBLE-BLIND; INADEQUATE RESPONSE; CLINICAL-TRIALS; ALLOPURINOL; FEBUXOSTAT; MULTICENTER; MANAGEMENT; LESINURAD; OUTCOMES; PLACEBO;
D O I
10.1016/j.semarthrit.2022.152049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To synthesize evidence of the effect of contextual factors (CFs) on efficacy of urate-lowering therapy (ULT) on serum urate (SU) as outcome in gout patients. Methods: Randomised controlled trials (RCTs) from (updated) Cochrane reviews were the starting point. RCTs were included if they explored the role of any CF on efficacy of ULT on SU in gout patients. For CFs with sufficient data (i.e. >= 3 trials), a mixed-effects meta-regression analysis was performed with trial and comparison as random effects, whereas specific CFs were modelled as fixed factors. Results: Eight RCTs were included. Effect modification by CFs was explored for age, sex, race, renal function, cardiovascular comorbidity, tophi, thiazide-diuretic use, and previous ULT use. Crude data stratified by renal function were available for four trials (36 randomised comparisons), and suitable for meta-analysis. Pooled estimates revealed that gout patients with a normal, mildly-, or moderately impaired renal function were consistently more likely to achieve SU target with ULT compared to control. Among RCTs comparing ULT to placebo (30 comparisons), effects of ULT on achieving SU target were not statistically different for those with normal (OR:66.87; [11.39-392.75]) compared to mildly (OR:28.54; [5.11-159.46]) and moderately (OR:21.45; [3.20-143.64]) impaired renal function, but seemed lower in those with severely impaired (OR:9.13; [0.96-86.97]) renal function. Data were insufficient to draw conclusions on effect modification by other CFs. Conclusion: Few RCTs report stratified analyses exploring the role of CFs. ULT seemed effective in reaching the SU target in all levels of renal function, though severely impaired renal function appeared to render a slight disadvantage.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Serum urate and gout flares on urate-lowering therapy
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2024, 6 (07): : E421 - E421
  • [2] Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis
    Stamp, Lisa
    Morillon, Melanie B.
    Taylor, William J.
    Dalbeth, Nicola
    Singh, Jasvinder A.
    Lassere, Marissa
    Christensen, Robin
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (02) : 293 - 301
  • [3] Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout
    Wei, Jie
    Choi, Hyon K.
    Dalbeth, Nicola
    Lane, Nancy E.
    Wu, Jing
    Lyu, Houchen
    Zeng, Chao
    Lei, Guanghua
    Zhang, Yuqing
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 (08) : 1456 - 1465
  • [4] Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis
    Yin, Rulan
    Li, Lin
    Zhang, Guo
    Cui, Yafei
    Zhang, Lijuan
    Zhang, Qiuxiang
    Fu, Ting
    Cao, Haixia
    Li, Liren
    Gu, Zhifeng
    BMJ OPEN, 2018, 8 (04):
  • [5] Improving adherence to urate-lowering therapy in people living with gout
    Coleshill, Matthew J.
    Aung, Eindra
    Nguyen, Amy D.
    Stocker, Sophie L.
    Baysari, Melissa T.
    Kamel, Bishoy
    Schulz, Marcel
    McLachlan, Andrew J.
    Day, Richard O.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (04) : 542 - 544
  • [6] Urate-lowering therapy in gout: determinants for achieving the serum target
    Brudermanns, Britta
    AKTUELLE RHEUMATOLOGIE, 2024, 49 (06) : 348 - 348
  • [7] EFFECT OF DIALYSIS AND LOW DOSE URATE-LOWERING ON SERUM URATE LEVELS IN PATIENTS WITH GOUT
    Urionaguena, I.
    Chinchilla, S. P.
    Garcia Erauzkin, G.
    Muniz-Gomez, M. L.
    Perez-Ruiz, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1363 - 1363
  • [8] Effect of Urate-Lowering Treatment on the Risk of Urolithiasis in People with Gout
    Lan, Wen-Ching
    Yu, Kuang-Hui
    Luo, Shue-Fen
    Kuo, Chang-Fu
    Chan, Tien-Ming
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [9] Factors influencing the response to urate-lowering therapy in patients with gout
    Cai, F.
    Rui, W.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1308 - 1308
  • [10] Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes A Systematic Review and Meta-Analysis
    Chen, Qi
    Wang, Zi
    Zhou, Jingwei
    Chen, Zhenjie
    Li, Yan
    Li, Shichao
    Zhao, Hukang
    Badve, Sunil V.
    Lv, Jicheng
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (11): : 1576 - 1586